Invenra Partners with Exelixis to Develop New Antibody Cancer Drugs
167152
post-template-default,single,single-post,postid-167152,single-format-standard,bridge-core-1.0.5,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive
 

Invenra Partners with Exelixis to Develop New Antibody Cancer Drugs

Invenra Partners with Exelixis to Develop New Antibody Cancer Drugs

Invenra, a URP tenant / biotech startup that develops therapeutic antibodies for pharma companies, is joining forces with a Bay Area company to discover and develop new treatments for cancer.

Under the agreement, Exelixis will pay Invenra $2 million upfront, plus an additional $2 million at the outset of each new discovery project, the company said. Exelixis will receive an exclusive global license to one preclinical asset, Invenra said.

READ THE FULL STORY